Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Assessment of T1695 Ophthalmic Suspension, Versus Ciclosporin Ophthalmic Emulsion, in Participants With Moderate to Severe Vernal Keratoconjunctivitis (VKC)

NCT07169695 is registered in ClinicalTrials.gov with Laboratoires Thea as lead sponsor.

NCT NCT07169695
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07169695 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Assessment of T1695 Ophthalmic Suspension, Versus Ciclosporin Ophthalmic Emulsion, in Participants With Moderate to Severe Vernal Keratoconjunctivitis (VKC)
Lead sponsor
Laboratoires Thea
Phase
Phase 2
Overall status
Recruiting
Start date
March 24, 2026
Completion date
January 21, 2027
Enrollment
120 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

moderate to severe vernal keratoconjunctivitis